Adagio Medical Holdings, Inc. (ADGM) Stock Score, Valuation & Financial Research

Adagio Medical Holdings, Inc. is in the Healthcare sector and Medical - Devices industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for ADGM

Adagio Medical Holdings, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 0.14. These figures are a research snapshot, not a buy or sell recommendation.

What Adagio Medical Holdings, Inc. does

Adagio Medical Holdings, Inc. is an emerging medical device firm focused on pioneering and commercializing innovative ablation technologies. Its core mission is to provide therapeutic solutions for various cardiac rhythm disorders, including but not limited to atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's current product portfolio showcases advanced offerings such as the iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and its complementary accessories, the vCLAS ventricular ULTC catheter, and the Cryopulse atrial pulsed-field cryoablation catheter, also available with associated accessories. This entity, which commenced operations in 2011, has its principal office situated in Laguna Hills, California.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Adagio Medical generates revenue primarily through the sale of its proprietary medical devices and associated consumables used in catheter ablation procedures. The company focuses on commercializing its ultra-low temperature cryoablation technology for the treatment of cardiac arrhythmias, selling these products to hospitals and electrophysiology laboratories.

Products and services

  • The company develops and markets catheter-based ultra-low temperature cryoablation (UTLC) systems, including the vCLAS catheter, designed for the treatment of ventricular tachycardia and other cardiac arrhythmias.

Brands and product families

  • vCLAS — Proprietary cryoablation catheter system. Source

Customer types

Hospitals; Electrophysiology Laboratories.

Suppliers, materials and equipment

  • Contract Manufacturers — The company relies on third-party contract manufacturers for the production of its medical device components and finished goods. Source

Business strengths to evaluate

  • Proprietary ultra-low temperature cryoablation (UTLC) technology Source

Business risks and research considerations

  • Dependence on clinical trial success and regulatory approvals Source
  • Limited operating history and history of losses Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

ADGM financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 0.14
Market capitalization:
3.07M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -27.14M
Free cash flow:
USD -19.39M
Cash:
USD 7.74M
Total debt:
USD 26M
EPS:
USD -1.43

What stands out

  • Free cash flow is USD -19.39M, negative for the stored period.
  • The balance sheet shows USD 7.74M of cash versus USD 26M of total debt, with debt exceeding cash on these two reported measures.
  • The current research record carries a corporate distress warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Debt exceeds cash by USD 18.26M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for ADGM

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can ADGM fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • Is ADGM's debt load manageable relative to cash generation, interest costs and upcoming maturities?
  • What specifically needs to improve for ADGM to reach sustainable profitability?
  • What does the current corporate distress warning mean for the reliability or interpretation of ADGM's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 73% of the scoring inputs required for this public page are currently available.

How to research ADGM

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.